Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (FATE)
NASDAQ:FATE
FATE Analyst Ratings
Moderate Buy
4 Buy
9 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
FATE Stock 12 Month Forecast
Average Price Target
$5.15
▲(305.51%Upside)
| Highest Price Target$12.00 | Average Price Target$5.15 | Lowest Price Target$2.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$1
Hold
-21.26%
Downside
Reiterated
05/20/25
Fate Therapeutics has significant financial challenges, with persistent losses and negative cash flow being the primary concerns. While technical indicators suggest mild bullish momentum, the stock's valuation remains difficult due to ongoing losses and no dividend yield. The company's low debt-to-equity ratio offers some financial stability, but strategic changes are essential for long-term viability. Investors should be cautious, given the high beta, indicative of potential volatility.
Wedbush
$5
Hold
293.70%
Upside
Reiterated
05/14/25
Barclays
$10→$2
Buy
57.48%
Upside
Reiterated
05/14/25
Oppenheimer
―
Hold
―
Reiterated
05/14/25
Robert W. Baird
$5→$4
Hold
214.96%
Upside
Reiterated
05/14/25
Leerink Partners
$12
Buy
844.88%
Upside
Reiterated
05/14/25
Wells Fargo
$4
Hold
214.96%
Upside
Reiterated
05/13/25
TD Cowen
―
Hold
―
Reiterated
05/13/25
Bank of America Securities
$3→$2.5
Hold
96.85%
Upside
Reiterated
03/07/25
Jefferies
$10→$8
Buy
529.92%
Upside
Reiterated
03/06/25
Morgan Stanley
$5
Hold
293.70%
Upside
Reiterated
03/06/25
Stifel Nicolaus
$5→$3
Hold
136.22%
Upside
Reiterated
03/06/25
Piper Sandler
$6
Buy
372.44%
Upside
Reiterated
03/06/25
H.C. Wainwright
$5
Hold
293.70%
Upside
Reiterated
08/22/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$1
Hold
-21.26%
Downside
Reiterated
05/20/25
Fate Therapeutics has significant financial challenges, with persistent losses and negative cash flow being the primary concerns. While technical indicators suggest mild bullish momentum, the stock's valuation remains difficult due to ongoing losses and no dividend yield. The company's low debt-to-equity ratio offers some financial stability, but strategic changes are essential for long-term viability. Investors should be cautious, given the high beta, indicative of potential volatility.
Wedbush
$5
Hold
293.70%
Upside
Reiterated
05/14/25
Barclays
$10→$2
Buy
57.48%
Upside
Reiterated
05/14/25
Oppenheimer
―
Hold
―
Reiterated
05/14/25
Robert W. Baird
$5→$4
Hold
214.96%
Upside
Reiterated
05/14/25
Leerink Partners
$12
Buy
844.88%
Upside
Reiterated
05/14/25
Wells Fargo
$4
Hold
214.96%
Upside
Reiterated
05/13/25
TD Cowen
―
Hold
―
Reiterated
05/13/25
Bank of America Securities
$3→$2.5
Hold
96.85%
Upside
Reiterated
03/07/25
Jefferies
$10→$8
Buy
529.92%
Upside
Reiterated
03/06/25
Morgan Stanley
$5
Hold
293.70%
Upside
Reiterated
03/06/25
Stifel Nicolaus
$5→$3
Hold
136.22%
Upside
Reiterated
03/06/25
Piper Sandler
$6
Buy
372.44%
Upside
Reiterated
03/06/25
H.C. Wainwright
$5
Hold
293.70%
Upside
Reiterated
08/22/24
Best Analysts Covering Fate Therapeutics
1 Month
xxx
Success Rate
7/18 ratings generated profit
Average Return
-0.87%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 38.89% of your transactions generating a profit, with an average return of -0.87% per trade.
3 Months
xxx
Success Rate
12/29 ratings generated profit
Average Return
-0.67%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 41.38% of your transactions generating a profit, with an average return of -0.67% per trade.
1 Year
Success Rate
5/18 ratings generated profit
Average Return
-18.54%
reiterated a buy rating 16 days ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 27.78% of your transactions generating a profit, with an average return of -18.54% per trade.
2 Years
xxx
Success Rate
3/18 ratings generated profit
Average Return
-49.73%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 16.67% of your transactions generating a profit, with an average return of -49.73% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
FATE Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
May 25
Strong Buy
7
6
4
6
7
Buy
3
2
0
0
0
Hold
23
14
2
9
15
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
33
22
6
15
22
Each month's total comprises the sum of three months' worth of ratings.
FATE Financial Forecast
FATE Stock Forecast FAQ
What is FATE’s average 12-month price target, according to analysts?
Based on analyst ratings, Fate Therapeutics’s 12-month average price target is 5.15.
What is FATE’s upside potential, based on the analysts’ average price target?
Fate Therapeutics has 305.51% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is FATE a Buy, Sell or Hold?
Fate Therapeutics has a consensus rating of Moderate Buy which is based on 4 buy ratings, 9 hold ratings and 0 sell ratings.
What is Fate Therapeutics’s price target?
The average price target for Fate Therapeutics is 5.15. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $12.00 ,the lowest forecast is $2.00. The average price target represents 305.51% Increase from the current price of $1.27.
The highest analyst price target is $12.00 ,the lowest forecast is $2.00. The average price target represents 305.51% Increase from the current price of $1.27.
What do analysts say about Fate Therapeutics?
Fate Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of FATE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.